Cell cycle-mediated drug resistance: An emerging concept in cancer therapy

Clinical Cancer Research

Volumn 7, Issue 8, 2001, Pages 2168-2181

  Shah, M A ^a   Schwartz, G K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; BRYOSTATIN 1; CAMPTOTHECIN; CISPLATIN; DOCETAXEL; FLAVOPIRIDOL; FLUOROURACIL; IRINOTECAN; PACLITAXEL; TAXANE DERIVATIVE;

APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE; DRUG EFFICACY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SHORT SURVEY; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CELL CYCLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 0034887884     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (169)

1. Experimental evaluation of potential anticancer agents. XIV. Further studies on certain basic concepts underlying chemotherapy of leukemia
2. Experimental evaluation of potential anticancer agents. XII. On the criteria and kinetics associated with curability of experimental leukemia
3. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate
4. Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer
5. Principles of cancer management: Chemotherapy
6. Conceptual basis for advances in the systemic drug therapy of breast cancer
7. Tumor size, sensitivity to therapy, and design of treatment schedules
8. Mutations of bacteria from virus sensitivity to virus resistance
9. A model for tumor response to chemotherapy: An integration of the stem cell and somatic mutation hypotheses
10. The biochemistry of P-glycoprotein-mediated multidrug resistance
11. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
12. Increased accumulation of vincristine and Adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors
13. CDK inhibitors: Positive and negative regulators of G1-phase progression
14. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)
15. Cyclins and cell cycle check-points
16. Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities
17. Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution
18. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis
19. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE
20. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
21. Degradation of lamin B1 precedes oligonucleosomal DNA fragmentation in apoptotic thymocytes and isolated thymocyte nuclei
22. Dysregulation of apoptosis in cancer
23. Apoptosis and cancer drug targeting
24. Apoptosis in cancer therapy: Crossing the threshold
25. Apoptosis. Its significance in cancer and cancer therapy
26. Cell death in health and disease: The biology and regulation of apoptosis
27. Implications of apoptotic cell death regulation in cancer therapy
28. Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis
29. Apoptosis: A basic biological phenomenon with wide ranging implications in tissue kinetics
30. Cell death: The significance of apoptosis
31. Induction of apoptosis-new targets of cancer chemotherapy
32. Defining apoptosis
33. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
34. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents
35. Bcl-2 and the regulation of programmed cell death
36. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2
37. Involvement of the bcl-2 gene in human follicular lymphoma
38. Apoptosis meets signal transduction: Elimination of a BAD influence
39. Opposing effects of ERK, JNK, and RK kinases on apoptosis
40. Direct evidence for involvement of mitogen-activated protein kinase (MAPK) rather than stress-activated protein kinase (SAPK), in potentiation of 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis by interruption of protein kinase C signaling
41. Cell cycle arrest versus cell death in cancer therapy
42. The problem of synergy and antagonism of combined drugs
43. Exploitable mechanisms in combined radiotherapy-chemotherapy. The concept of additivity
44. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
45. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines
46. In vitro toxicity of Taxol based anticancer drug combinations on human hematopoietic progenitors
47. What is synergy?
48. The search for synergy: A critical review from response surface perspective
49. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents
50. Promotion of microtubule assembly in vitro by Taxol
51. Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins
52. Taxol stabilizes microtubules in mouse fibroblast cells
53. 1 arrest in gastric cancer cells
54. 1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase
55. A Phase I trial of Taxol given by a 6-hour intravenous infusion
56. cdc2 coincident with Taxol-induced apoptosis
57. Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with Taxol
58. Temporal and spatial control of cyclin B1 destruction in metaphase
59. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cipl which inhibits p34Cdc2 kinase
60. Cytotoxicity of the anticancer agents cisplatin and Taxol during cell proliferation and the cell cycle
61. Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death
62. Phosphorylation of Bcl-2 protein and association with p21Ras in Ras-induced apoptosis
63. Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis
64. Bcl-xl overexpression inhibits Taxol-induced yama protease activity and apoptosis
65. Overexpression of Bcl-xl by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation
66. Molecular effects of paclitaxel: Myths and reality
67. Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific related mortality of transformed cells
68. Paclitaxel-induced cell death
69. An antiinflammatory cum immunodulatory piperidinylbenzopyranone from Dysoxylum binectariferum: Isolation, structure, and total synthesis
70. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275
71. 1 arrest with inhibition of cyclin-dependent kinase CDC2 and CDK4 in human breast carcinoma cells
72. Inhibition of CDK2, CDK4 and CDK7 by flavopiridol and structural analogs
73. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C
74. The in vitro effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow
75. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin-1 correlates with the dephosphorylation of cyclin-dependent kinase 2
76. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells
77. Inappropriate cell cycle progression enhances the induction of apoptosis by flavopiridol in Taxol treated gastric cancer cells
78. A Phase I trial of weekly sequential bryostatin (Bryo) and paclitaxel in patients with advanced solid tumors
79. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
80. Bcl-xL modulates apoptosis induced by anticancer drugs and delays DEVDase and DNA fragmentation-promoting activities
81. Bryostatin-1 enhances paclitaxel induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xl
82. Effect of bryostatin-1 on Taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937)
83. Phase I study of sequential paclitaxel and the cyclin dependent kinase inhibitor flavopiridol
84. 2 arrest and DNA double strand breaks
85. Premature mitosis induced in mammalian cells by the protein kinase inhibitors 2-aminopurine and 6-dimethylaminopurine
86. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells
87. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro
88. Cisplatin and its analogues
89. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia
90. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: Possible explanation for failure of combination therapy
91. DNA damage and cell cycle checkpoints
92. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents
93. Increased accumulation of p53 protein in cisplatin-resistant cell lines
94. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems
95. Induction of apoptosis by Taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cancer cells
96. Influence of Taxol: Cisplatin sequencing on cisplatin-DNA adduct repair in human ovarian cancer cells
97. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents Taxol and vincristine
98. In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines
99. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells
100. Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro
101. Sequence-dependent antitumor activity of paclitaxel (Taxol) and cisplatin in vivo
102. Action of hydrolyzed cisplatin and some analogs on microtubule protein polymerization in vitro
103. Synergistic interaction between cisplatin and Taxol in human ovarian carcinoma cells in vitro
104. In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules
105. Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo
106. Sequences of Taxol and cisplatin: A phase I and pharmacologic study
107. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells
108. A Phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancer
109. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer
110. A Phase II study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracycline-based chemotherapy
111. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A Phase II study
112. Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: An Eastern Cooperative Oncology Group Study
113. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: An active regimen with limiting neurotoxicity
114. Camptothecin discovery to clinic
115. The current status of camptothecin analogues as antitumor agents
116. Action of camptothecin on mammalian cells in culture
117. Topoisomerase I inhibitors. Topotecan and irinotecan
118. Camptothecin induces protein-linked DNA breaks via mammalian Topoisomerase I
119. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
120. 1 arrest followed by necrotic cell death
121. 2 arrest: Altered regulation of p34cdc2/cyclin B
122. Topoisomerase-1 inhibitors for human malignant glioma: Differential modulation of p53, p21, bax, and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and β-lapachone
123. Unscheduled activation of cyclin B1/cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage
124. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair
125. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors
126. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal carcinoma
127. Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecan injection) in Japan
128. 1 arrest in human cancer cells
129. Requirement for p53 and p21 to sustain G2 arrest after DNA damage
130. Cooperative effects of genes controlling the G2/M checkpoint
131. p21 inhibits Thr161 phosphorylation of cdc2 to enforce the G2 DNA damage checkpoint
132. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines
133. waf1/cip1 in HCT116 cells
134. 2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells
135. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells
136. Antimetabolites
137. Kinetics and thermodynamics of the interaction of 5-fluoro-2′-deoxyuridylate with thymidylate synthase
138. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines
139. Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells
140. Effect of 5-fluorouracil on cell cycle regulatory proteins in human colon cancer cell line
141. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo
142. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines
143. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line
144. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: Role of drug sequence and dose
145. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: Elevated dTTP pools and enhanced cytotoxicity
146. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer
147. A Phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer
148. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: A Phase I study of the Southern Italy Cooperative Oncology Group
149. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer
150. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
151. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. Purification, physico-chemical properties, structural determination and biological activities
152. Potent and specific inhibitors of PKC of microbial origin
153. UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
154. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function
155. 2-checkpoint inhibitor
156. 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells
157. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation
158. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1
159. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
160. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells
161. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells
162. UCN-01, 7-hydroxylstaurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line
163. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/CIP/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells
164. The retinoblastoma gene product is a negative modulator of the apoptotic pathway
165. Transcriptional regulation of mouse dihydrofolate reductase in the cell cycle
166. Cell-cycle-directed regulation of thymidylate synthase messenger RNA in human diploid fibroblasts stimulated to proliferate
167. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner